Acadia’s remlifanserin narrowly missed its Phase 2 primary endpoint in Alzheimer’s psychosis. Safety remained favorable, Phase 3 is continuing, and the stock sold off first.
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
BofA upgrades Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target.
Mizuho upgrades ACAD stock to Outperform with a $35 price target, highlighting undervalued potential in remlifanserin for Alzheimer’s psychosis, despite past setbacks with pimavanserin.
Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.
Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.
